Stockscreener 앱 받기
10.26
0.39%
-0.04
시간 외 거래:
10.26
Design Therapeutics Inc 주식(DSGN)의 최신 뉴스
Aug EndMonth: Will Design Therapeutics Inc benefit from green energy policies2026 Buyback Activity & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Design Therapeutics (DSGN) Receives a New Rating from a Top Analyst - The Globe and Mail
Design Therapeutics (NASDAQ:DSGN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Jefferies Initiates Coverage On Design Therap... - Benzinga
Design Therapeutics (NASDAQ:DSGN) Now Covered by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage on Design Therapeutics With Buy Rating, $15 Price Target - marketscreener.com
Jefferies initiates coverage of Design Therapeutics (DSGN) with buy recommendation - MSN
Jefferies initiates Design Therapeutics stock with buy on drug potential - Investing.com
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program - Yahoo Finance
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% on Analyst Upgrade - Defense World
Design Therapeutics Inc devrait afficher une perte de 33 cents par actionEarnings AVANT-PAPIER - TradingView
[SCHEDULE 13D/A] Design Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Aug Breakouts: Can Design Therapeutics Inc expand its profit margins2026 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Piper Sandler reiterates Overweight on Design Therapeutics stock By Investing.com - Investing.com South Africa
RBC Capital raises Design Therapeutics stock price target on programs By Investing.com - Investing.com Australia
Design Therapeutics, Inc. 2025 Annual Report: GeneTAC® Platform, Genomic Medicine Strategy, and Pipeline Overview - Minichart
Royal Bank Of Canada Forecasts Strong Price Appreciation for Design Therapeutics (NASDAQ:DSGN) Stock - MarketBeat
RBC Capital raises Design Therapeutics stock price target on programs - Investing.com
Piper Sandler reiterates Overweight on Design Therapeutics stock - Investing.com
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - Bitget
Design Therapeutics (NASDAQ:DSGN) Announces Earnings Results - MarketBeat
Design Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
DSGN: GeneTACⓇ platform advances four programs for genetic diseases, with strong clinical and financial momentum - TradingView
Design Therapeutics Provides Update on Clinical Trials and Financial Position for 2025 - Quiver Quantitative
Design Therapeutics reports lower-than-expected Q4 net loss - TradingView
DSGN: Net loss rose to $69.8M in 2025 as R&D spending increased; $219.8M cash at year-end - TradingView
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
GeneTAC pipeline advances at Design Therapeutics (NASDAQ: DSGN) in FA, FECD, DM1 and HD - Stock Titan
DSGN: Clinical pipeline advanced, net loss $69.8M, cash reserves $219.8M fund operations into 2029 - TradingView
Design Therapeutics (Nasdaq: DSGN) widens 2025 loss but keeps $219.8M cash - Stock Titan
Three genetic disease trials push ahead at Design Therapeutics - Stock Titan
Stock Report: Is Design Therapeutics Inc currently under institutional pressureJuly 2025 Selloffs & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Design Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Earnings Risk: Will Design Therapeutics Inc benefit from green energy policies2025 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn
Antiverse Raises $9.3M Series A to Develop Antibodies for Undruggable Disease Targets and Announces Research Agreement with the Cystic Fibrosis Foundation - Business Wire
Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday - MarketBeat
DSGNDesign Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference - Defense World
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Kymera Therapeutics (KYMR) and Argenx Se (ARGX) - The Globe and Mail
DSGN.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
DSGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Fuchs Dystrophy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen - Barchart.com
Stock List: Research Stocks from Around the World - GuruFocus
DSGN: Clinical-stage genetic medicine programs in FA, FECD, and DM1 advance toward key data readouts - TradingView
Design Therapeutics (NASDAQ:DSGN) Hits New 1-Year HighWhat's Next? - MarketBeat
LEVI & KORSINSKY, LLP INVESTIGATING ALLEGED CLINICAL TRIAL DESIGN DEFICIENCIES AT VISTAGEN THERAPEUTICS -- CLASS ACTION FILED - PR Newswire
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 - The Manila Times
K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026 - PR Newswire
DSGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
1.20%
0.06%
자본화:
|
볼륨(24시간):